Elranatamab is a BCMA–CD3 T-cell-engaging bispecific antibody (BsAb) that links BCMA on myeloma cells with CD3 on T cells, redirecting T-cell cytotoxicity toward myeloma cells and mediating antitumor effects [6, 7]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.